Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”). Proposed privatisation of Kangji Medical Holdings Limited The Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and incl...
Survey reveals tech adoption gap despite industry focus on trial efficiency ...
Targeting diverse diabetic population to enhance early detection of diabetic retinopathy ...
New feature enables compatibility with almost any fluoroscopic C-arm, advancing global lung cancer diagnostics...
Trial to assess Calibreye™ Titratable Glaucoma Therapy™ Surgical System in refractory glaucoma patients ...
Funding boost to support pivotal trial and pre-commercialization of CLAAS® AcuFORM™ LAAO system. ...
Authority to Operate (ATO) certification from the U.S. Department of Defense affirms Dräger’s leadership in safeguarding patient data, delivering a fully ATO-certified anesthesia portfolio trusted by hospitals worldwide....
The acquisition reinforces Sarnova's and Cardio Partners' long-term support for vendors and partners while opening new opportunities for collaboration...
Founded in 2009, QinFlow is a market leader in fluid thermoregulation solutions. ...
New system empowers sterile processing departments with the fastest FDA-cleared readout on the market, enabling real-time decision-making and elevating operational efficiency. ...
